Atracare can Treat your COVID: Now

Atracare has always had a mission to bring patients the care they need right here is Sussex County.  That is why we are proud to offer the treatment for COVID positive patients when they need it most, right away.

What is Bebtelovimab?

  • Bebetlovimab is a monoclonal antibody used to treat patients with COVID.
  • It is given as a slow IV injection over 30 seconds.  Then patients are monitored for 1 hour after the infusion to ensure there is no reaction.
  • The dosage is bebtelovimab 175 mg administered as a single intravenous injection over at least 30 seconds.
  • It is designed to neutralized COVID and prevent further injury or death from the virus.

Who can get Bebtelovimab?

  • This medication is for anyone ≥12 years of age and weighing at least 40 kg.
  • Bebtelovimab is recommended to be given as soon as possible after a positive COVID test and within 7 days of symptom onset.

How can I get Bebtelovimab?

  • We offer infusions at our main clinic in Lewes from 8AM to 8PM.
  • Text us at (302) 517-1385 any time if you need assistance or would like to schedule.
  • Click the link below to schedule an appointment at our Walk-In (Urgent Care) Clinic.

Press Release on Bebtelovimab

 

[Feb 11, 2022] From the FDA

Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for a new monoclonal antibody for the treatment of COVID-19 that retains activity against the omicron variant. The EUA for bebtelovimab is for the treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kilograms, which is about 88 pounds) with a positive COVID-19 test, and who are at high risk for progression to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options approved or authorized by the FDA are not accessible or clinically appropriate.

Bebtelovimab is not authorized for patients who are hospitalized due to COVID-19 or require oxygen therapy due to COVID-19. Treatment with bebtelovimab has not been studied in patients hospitalized due to COVID-19. Monoclonal antibodies, such as bebtelovimab, may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high flow oxygen or mechanical ventilation.